drugset / Trial / NCT03400306

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

NCT03400306

Phase 1 Withdrawn AbbVie
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.

Timeline

Start
2021-11-15
Primary completion
2021-11-16
Completion
2021-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Veliparib Small molecule 400 mg Oral
Background Carboplatin Small molecule Intravenous
Background Paclitaxel Small molecule Intravenous

Indications